Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics (CMPX) reported that the U.S. FDA has recommended conducting an additional trial showing an overall survival benefit before submitting a Biologics License Application (BLA) for tovecimig in previously treated, advanced biliary tract cancer (BTC).
The company does not believe a new trial is warranted before BLA submission, citing the Phase 2/3 COMPANION-002 study, in which tovecimig plus paclitaxel achieved a statistically significant improvement in objective response rate (18.0% vs. 5.3%; p=0.0228) and progression-free survival (median 4.7 vs. 2.6 months; hazard ratio 0.44; p<0.0001) versus paclitaxel alone. Overall survival did not reach statistical significance due to high crossover and prolonged survival in crossover patients. Compass plans further engagement with the FDA while preparing a BLA and states that the safety profile was generally consistent with prior tovecimig studies.
Compass Therapeutics (Nasdaq: CMPX) reported 2026 Q2 results and a corporate update, highlighting progress across its oncology pipeline and liquidity of $180 million in cash and marketable securities as of June 30, 2026, which the company expects will fund operations into 2028.
For biliary tract cancer, final Phase 2/3 data for tovecimig showed an ORR of 18.0% (20/111) in the combination arm versus 5.3% for paclitaxel alone, with a p-value of 0.0228; FDA feedback on these data is expected in Q3 ahead of a potential BLA filing later in 2026, and the dataset will be presented orally at ESMO. CTX-8371 Phase 1 cohort expansions in multiple tumors are enrolling, with additional data expected in Q4 2026, CTX-10726 first-in-human dosing has begun with initial data also expected in Q4, and a Phase 2 study of CTX-471 in NCAM(CD56)-positive tumors is planned to start in Q3.
Net loss was $25.2 million for Q2 2026 versus $19.9 million a year earlier, driven by higher R&D and pre-commercialization G&A expenses.
Compass Therapeutics (Nasdaq: CMPX) reported that its abstract, “A randomized trial of paclitaxel ± tovecimig in previously treated patients with advanced biliary tract cancer,” has been accepted for an oral Proffered Paper presentation at the ESMO Congress 2026 in Madrid, Spain.
The presentation will cover results from the randomized, controlled Phase 2/3 COMPANION-002 trial evaluating tovecimig, a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel in patients with advanced biliary tract cancer. According to Compass Therapeutics, Dr. Nilofer Azad of Johns Hopkins University will present on Saturday, October 24, 2026, during a session scheduled from 10:15am–11:45am CET.
Compass Therapeutics (Nasdaq:CMPX) will participate in two June 2026 investor conferences focused on healthcare.
Management will present at the Jefferies Global Healthcare Conference on June 4 at 8:45 AM ET and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 at 8:00 AM ET, with webcasts and replays available.
Compass Therapeutics (Nasdaq:CMPX) will present Phase 1 data for CTX-8371, a dual PD-1×PD-L1 bispecific antibody, in advanced malignancies post-checkpoint inhibition at the 2026 ASCO Annual Meeting.
Among 15 evaluable patients, three responses were reported, with a 33% ORR at higher doses and no dose-limiting toxicities.
Compass Therapeutics (Nasdaq:CMPX) will participate in two May 2026 investor conferences focused on biotechnology and oncology.
The company presents at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19 at 1:30 PM ET, and at the 2026 Stifel Virtual Targeted Oncology Forum on May 20 at 11:30 AM ET. Both presentations are accessible via webcast, with replays available on the company’s Events page. Management will be available for one-on-one investor meetings arranged through conference representatives.
Compass Therapeutics (Nasdaq: CMPX) reported Q1 2026 results and a corporate update on May 5, 2026. Key clinical highlights include positive Phase 2/3 data for tovecimig (ORR 17.1% vs 5.3%, PFS 4.7 vs 2.6 months, HR=0.44, p<0.0001) and FDA Orphan Drug designation; company plans a pre-BLA meeting and a BLA later this year. CTX-8371 cohort expansions and an ASCO 2026 poster were announced; CTX-10726 Phase 1 initiated with initial data expected in Q4 2026. Financials: net loss $18.3M; cash and marketable securities $195M, runway into 2028.
Compass Therapeutics (Nasdaq: CMPX) reported COMPANION-002 results showing tovecimig plus paclitaxel met key secondary PFS and primary ORR endpoints in second-line biliary tract cancer. Median PFS was 4.7 vs 2.6 months (HR=0.44, p<0.0001). ORR was 17.1% vs 5.3% (p=0.031). OS was confounded by 54% crossover; pooled median OS was 8.9 months. Safety: hypertension and neutropenia were notable. Company plans an FDA meeting ahead of a planned BLA and will present full data at a medical conference.
Compass Therapeutics (Nasdaq: CMPX) will host a webcast on Monday, April 27, 2026 at 8:00am ET to review topline secondary endpoints from its Phase 2/3 COMPANION-002 study of tovecimig (a DLL4 x VEGF-A bispecific antibody) plus paclitaxel in advanced biliary tract cancer.
Dial-in numbers and a webcast URL are provided; a replay and accompanying presentation will be available for 90 days on the company’s Investors Events page.
Compass Therapeutics (Nasdaq: CMPX) reported 2025 results and a corporate update on March 5, 2026. Key clinical milestones include tovecimig meeting the primary ORR endpoint in COMPANION-002 and planned PFS/OS analyses in April 2026. CTX-8371 expansion cohorts for TNBC and NSCLC are open; an HL cohort will be added. The IND for CTX-10726 was cleared and Phase 1 will open in Q1 2026. Leadership changes include promotion of Bing Gong to CSO and new CMO/CCO hires. Cash and marketable securities were $209 million at year-end 2025, with runway into 2028.